Glaukos Raises 2026 Sales Guidance Following 50% Q2 Revenue Growth

Key Facts

1Glaukos achieved 50% YoY Q2 net sales growth reaching $185.6 million.

2Management raised 2026 net sales guidance to a range of $680–700 million.

3Non-GAAP gross margin reached 85% as the company hit breakeven P&L.

Glaukos achieved 50% year-over-year net sales growth in the second quarter, reaching $185.6 million, Seeking Alpha reported. Following the performance, management raised its 2026 net sales guidance to a range of $680 million to $700 million.

Financial results showed a non-GAAP gross margin of 85% as the company reached a breakeven P&L position. Shares of GKOS closed at $165.69 on October 9, 2026, as the firm continues its transition into a diversified ophthalmic pharmaceutical platform supported by its J-code drug expansion.